quinine sulfate + clindamycin

Quinamycine is a fixed-dose combination antimalarial medication developed and manufactured by Pharmakina in the Democratic Republic of the Congo. It consists of quinine sulfate (250 mg) and clindamycin (150 mg). Quinine is a cinchona alkaloid that acts as a rapidly acting blood schizonticide by inhibiting the polymerization of toxic heme into non-toxic hemozoin within the malaria parasite's food vacuole. Clindamycin is a lincosamide antibiotic that targets the parasite's apicoplast, inhibiting protein synthesis. This combination is specifically indicated for the treatment of uncomplicated malaria, particularly in cases where resistance to other antimalarials is suspected or confirmed. The addition of clindamycin to quinine is intended to enhance efficacy and potentially allow for shorter treatment courses compared to quinine monotherapy. Quinamycine is formulated as oral tablets and is an established product in the Central African pharmaceutical market.

Brand names

Quinamycine

Other names

Quinamycinequinine sulfate + clindamycinquinine + clindamycin